BCL2 (B-cell CLL/lymphoma 2)

Collectively, these findings suggest that IRAIN may participate in the regulation of proliferation, apoptosis, and cell cycle progression in MCL cells, potentially through modulation of LSD1. These results provide preliminary experimental evidence for further understanding the potential biological function of IRAIN in MCL.

Lan C exhibits measurable but relatively low cardiotoxicity at concentrations effective against cholangiocarcinoma, with cardiac effects may be manageable at therapeutic doses. These findings support Lan C as a promising anti-tumor candidate with controllable cardiotoxicity under optimized dosing and clinical monitoring.

CGGD primarily intervenes in STC combined with depression through pathways including the phosphatidylinositol 3-kinase-Akt signaling pathway, the mitogen-activated protein kinase signaling pathway, and the apoptosis pathway. Through an integrated network pharmacology approach, this study describes the synergistic effects of multiple ingredients, targets, and pathways of CGGD in the treatment of STC combined with depression.

Moreover, PAX alone significantly upregulated CASP1 and CASP3 expression, while co-treatment with SA significantly downregulated these genes. These findings highlight the protective role of SA in reducing PAX-induced toxicity, particularly in hepatic tissues, suggesting that SA could be a potential adjunct therapy for minimizing chemotherapy-related side effects.

The biocompatibility and targeting efficiency of bacterial EVs position them as a novel therapeutic platform for gastrointestinal cancers. This study provides the first preclinical evidence supporting the use of non-pathogenic bacterial exosomes in oncology, highlighting their translational potential for improving treatment outcomes in pancreatic cancer.

LIEE exhibits significant anti-osteoporotic effects through a multi-targeted mechanism involving modulation of ER/OPG/RANKL signalling, suppression of inflammation and oxidative stress, and regulation of key molecular targets. These outcomes propose that LIEE could help as a capable phytotherapeutic candidate for the management of postmenopausal osteoporosis and warrant more clinical exploration.

Because pathway-causality was not tested using NF-κB rescue or pharmacological inhibition controls, the mechanistic conclusions are presented as supportive associations rather than definitive proof. Future studies should focus on bioassay-guided compound purification, synergistic combination assessment, and in vivo validation for translational advancement.

Synergistic gene regulation was introduced by co-delivering BCL2 antisense oligonucleotide and BSeTPE-Pt-ac with amphiphilic tumor-targeting polymers, which effectively silenced BCL2 expression, overcame thermal resistance, and thus maximized the chemo-PTT efficacy of BSeTPE-Pt-ac. Our work elucidates the rational design of a multifunctional platinum(II) agent by effectively integrating key anticancer functionalities, offering valuable insights into the development of advanced multifunctional agents.

P1/2, N=258, Recruiting, BeOne Medicines | N=56 --> 258 | Trial completion date: Dec 2027 --> Nov 2032 | Active, not recruiting --> Recruiting | Trial primary completion date: Jun 2027 --> Nov 2029

Subsequent structural determination of LCDV2 Bcl-2 in complex with the BH3 domain of zBaxA demonstrated that they interact in a canonical manner, primarily mediated by the BH3 consensus motif residues of zBaxA. In addition, a subpocket formed by two phenylalanine residues in LCDV2 Bcl-2 plays a key role in determining binding selectivity.

Emerging treatments, including BCL-2-targeted therapy, bispecific antibodies, chimeric antigen receptor T-cell therapy, and possibly fibril-directed approaches, further expand the therapeutic landscape. This review summarizes contemporary concepts in the pathobiology, diagnosis, and management of systemic light-chain amyloidosis, with an emphasis on practical diagnostic algorithms, evolving response assessment, and remaining challenges in achieving durable organ recovery and sustained survival.

NP at its IC50 concentration showed a stronger ability to increase the apoptotic cell rate, inhibit cancer cell migration, suppress cancer cell growth through G1-phase arrest, and increase radioprotective effects in the normal cell line, while also increasing radiosensitivity in the cancer cell line compared with PE. NP demonstrated better and more effective activity against A-375 melanoma cells than PE.